Prague, Czech Republic
24 - 28 April 2010



Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs.

Headquartered in Geneva, Switzerland, Merck Serono is active on all continents. With around 17,000 employees worldwide, the division offers leading brands in 150 countries. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.

Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets.

Merck Serono combines expertise in New Chemical Entities (NCEs) and New Biological Entities (NBEs) to offer innovative prescription drugs of either origin. Biotech products generate around 60% of Merck Serono’s sales.

Excellence in research and development is a key success factor for Merck Serono. With an integrated R&D capability, as well as a network of alliances with other biopharmaceutical companies and academic groups, Merck Serono invests around 22% of total revenues or over €1bn each year to discover and develop new therapies. Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

Merck Serono was established on January 5, 2007 following the acquisition of Serono by Merck and the integration of its business with the former Merck Ethicals division.

Merck is a global pharmaceutical and chemical company with a history that began in 1668 and a future shaped by around 33,000 employees in 61 countries. Merck’s operating activities come under the umbrella of Merck KGaA, which is listed on the Frankfurt Stock Exchange and a member of the DAX® 30 Index.

For further information, please visit http://www.merckserono.com or http://www.merck.de